---
id: 150
title: Mycoplasma pneumoniae Infections
category: organisms
subcategory: atypical_bacteria
tags: [Mycoplasma, walking-pneumonia, macrolide, cold-agglutinins, erythema-multiforme]
difficulty: easy
---

## Question

What are the key clinical features and treatment of *Mycoplasma pneumoniae*? Use the **"Walking Pneumonia, Cold Agglutinins, Macrolide/Doxy × 5-7d"** framework.

## Answer

### ***Mycoplasma pneumoniae* Overview:**

**Transmission:** Respiratory droplets, **incubation 1-4 weeks** (slow progression)

**Epidemiology:**
- **Most common** in school-age children/young adults (5-20 years)
- **Outbreaks:** Schools, military barracks, close-contact settings
- **Seasonal:** Late summer/fall

### **Clinical Presentation:**

**Community-Acquired Pneumonia ("Walking Pneumonia"):**
- **Gradual onset** (over days to weeks)
- **Prominent cough:** Dry, persistent, hacking cough (hallmark)
- **Minimal systemic symptoms:** Low-grade fever, malaise, headache
- **CXR:** Patchy infiltrates (often worse than clinical exam suggests - "looks better than CXR")
- **Self-limited** in most cases (symptoms improve even without treatment, but antibiotics shorten duration)

**Extrapulmonary Manifestations:**

**Dermatologic:**
- **Erythema multiforme** (target lesions)
- **Stevens-Johnson syndrome** (rare, severe)
- **Maculopapular rash**

**Hematologic:**
- **Cold agglutinin disease:** IgM antibodies → hemolytic anemia (acrocyanosis, Raynaud phenomenon)

**Neurologic:**
- **Meningoencephalitis** (rare)
- **Guillain-Barré syndrome** (rare)
- **Transverse myelitis** (rare)

**Cardiac:**
- **Myocarditis, pericarditis** (rare)

### **Diagnosis:**

**Clinical Diagnosis:** Often presumed based on clinical presentation (young patient, gradual onset, dry cough, "walking pneumonia")

**Laboratory:**
- **PCR** (respiratory panel) - preferred, rapid, sensitive
- **Serology:** IgM (acute infection), 4-fold rise in IgG (convalescent, not useful for acute management)
- **Cold agglutinins:** Positive in ~50% (titer ≥1:64), NOT specific (can occur with EBV, CMV, lymphoma)

**CXR:**
- **Patchy infiltrates** (reticulonodular or interstitial)
- **Unilateral > bilateral**
- **Pleural effusion** uncommon

### **Treatment:**

**Preferred Agents:**
- **Azithromycin 500mg PO × 1, then 250mg PO daily × 4 days** (total 5 days)
- **Doxycycline 100mg PO BID × 7 days**

**Alternative:**
- **Levofloxacin 750mg PO daily × 5 days** (fluoroquinolone)
- **Clarithromycin 500mg PO BID × 7 days**

**Duration:** 5-7 days

**Notes:**
- **β-lactams ineffective** (*Mycoplasma* lacks cell wall)
- **Macrolide resistance increasing** (5-30% in some regions, East Asia highest)
- **Treat empirically for CAP** if suspected (covers typical + atypical)

## Key Points

### **"Walking Pneumonia":**
- **Ambulatory patient** with pneumonia (feels well enough to walk around)
- **Gradual onset, dry cough** (days to weeks)
- **Looks better than CXR** (patchy infiltrates, minimal exam findings)
- **Self-limited** in most cases

### **Cold Agglutinins:**
- **IgM antibodies** that agglutinate RBCs at cold temperatures
- **Hemolytic anemia:** Acrocyanosis (blue discoloration of extremities in cold), jaundice
- **Bedside test:** Blood clumps when cooled, unclumps when warmed
- **Positive in ~50%** of *M. pneumoniae* infections (NOT specific)

### **Extrapulmonary Manifestations:**
- **Erythema multiforme** (target lesions) - most common rash
- **Stevens-Johnson syndrome** (rare but serious)
- **Neurologic:** Meningoencephalitis, Guillain-Barré (rare)
- **Often occur AFTER respiratory symptoms resolve**

### **β-Lactams Ineffective:**
- ***Mycoplasma* lacks peptidoglycan cell wall** → intrinsically resistant to β-lactams
- **Always cover with macrolide/doxycycline/fluoroquinolone** if atypical CAP suspected

### **Macrolide Resistance:**
- **Mechanism:** 23S rRNA mutations
- **Prevalence:** 5-30% (highest in East Asia, up to 90% in some regions)
- **Consider doxycycline or fluoroquinolone** if treatment failure

### **Clinical Pearls:**
- **Walking pneumonia** in young patient with **dry cough** × weeks
- **Cold agglutinins + erythema multiforme** = classic extrapulmonary findings
- **Macrolide (azithromycin) or doxycycline × 5-7 days**
- **β-lactams ineffective** (no cell wall)
- **CXR often worse than clinical exam**
- **Self-limited**, but antibiotics shorten duration

## Sources

- [IDSA/ATS: Community-Acquired Pneumonia Guidelines 2024]
- [CDC: *Mycoplasma pneumoniae* Surveillance 2024]

## Media

N/A
